ProNAi Initiates ‘Brighton’ Phase II Trial of PNT2258 in Patients with Richter’s Transformation

VANCOUVER, Oct. 29, 2015 /CNW/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform, today announced it has enrolled the first patient into the “Brighton” study, a Phase 2 clinical trial evaluating PNT2258 in patients with Richter’s transformation. The international multi-center trial is expected to enroll approximately 50 patients with this rare form of cancer for which there are currently no approved therapies. Read more:  ProNAi Initiates ‘Brighton’ Phase II Trial of PNT2258 in Patients with Richter’s Transformation